Soluble IL-2R as a Marker of T Cell Activation in Immune-Mediated Diseases: Review and Case-Based Interpretation
Open Access
- 9 January 2025
- journal article
- review article
- Published by MDPI AG in Lymphatics
- Vol. 3 (1) , 1
Abstract
The soluble interleukin-2 receptor (sIL-2R) is a novel biomarker associated with a variety of immune-mediated diseases. It is produced through the proteolytic cleavage of the membrane-bound interleukin-2 receptor α-chain on activated T lymphocytes; hence, its increase reflects T-cell activation and immune dysregulation. Elevated sIL-2R levels are frequently documented in conditions such as rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, relapsing polychondritis, histiocytosis, hemophagocytic lymphohistiocytosis, lymphomas, and graft-versus-host disease, suggesting a potential role in monitoring disease activity and progression. However, sIL-2R levels may increase in the context of immune response to infections and malignancies, requiring careful interpretation. It is essential to determine whether elevated levels of this marker within specific ranges could suggest a specific entity, due to the implications this may have for the management of patients. This case-based review presents five patients with different immune-mediated diseases, highlighting how these different conditions can present with characteristic ranges of sIL-2R elevation. By integrating clinical findings with sIL-2R measurements, we emphasize the biomarker’s utility in guiding diagnosis, as well as monitoring disease activity and determining prognosis, which can enhance clinical decision-making and patient management in rheumatology and related fields.Keywords
This publication has 21 references indexed in Scilit:
- Increased serum soluble interleukin-2 receptor levels in dermatomyositis are associated with Th17/Treg immune imbalanceClinical and Experimental Medicine, 2023
- Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapyBest Practice & Research Clinical Rheumatology, 2020
- High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective StudyClinical Lymphoma Myeloma and Leukemia, 2019
- A comprehensive review on adult onset Still's diseaseJournal of Autoimmunity, 2018
- Treatment of Idiopathic Castleman DiseaseHematology/Oncology Clinics of North America, 2018
- Diagnostic Value of Serum-Soluble Interleukin 2 Receptor Levels vs Angiotensin-Converting Enzyme in Patients With Sarcoidosis-Associated UveitisJAMA Ophthalmology, 2017
- Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donorsInternational Journal of Hematology, 2016
- The tumour microenvironment in B cell lymphomasNature Reviews Cancer, 2014
- Cytokines in inflammatory bowel diseaseNature Reviews Immunology, 2014
- Interleukin 6: from bench to bedsideNature Clinical Practice Rheumatology, 2006